Demographic and clinical characteristics of patients with early axSpA at the inclusion in the DESIR cohort
| Patients at baseline N=702 | Patients with PGA and PhGA available over 36 months N=401 | |
|---|---|---|
| Age, years, mean (SD) | 33.8 (8.6) | 34.6 (8.7) |
| Sex (female), N (%) | 379 (54.0) | 219 (54.6) |
| Ethnicity (Caucasian), N (%) | 629 (89.6) | 369 (92.0) |
| Level of education (postsecondary), N (%) | 416 (59.3) | 252 (62.8) |
| Paid work status, N (%) | 204 (29.1) | 136 (33.9) |
| Duration of symptoms, months, mean (SD) | 18.1 (10.5) | 17.8 (10.7) |
| HLA-B27, N (%) | 409 (58.3) | 244 (60.9) |
| C reactive protein >5 mg/L, N (%) | 221 (31.5) | 130 (32.4) |
| Past history of peripheral arthritis, N (%) | 401 (57.1) | 231 (57.6) |
| Past history of extra-articular manifestations, N (%) | 186 (26.5) | 114 (28.4) |
| Radiological or MRI sacroiliitis, N (%) | 304 (43.3) | 184 (45.9) |
| Pain (0–10), mean (SD) | ||
| Spine | 5.3 (2.5) | 5.3 (2.5) |
| Joints | 2.7 (2.7) | 2.7 (2.8) |
| Fatigue (0–10), mean (SD) | 5.7 (2.4) | 5.7 (2.3) |
| BASFI (0–100), mean (SD) | 30.4 (22.8) | 29.7 (22.8) |
| SF-36, mean (SD) | ||
| MCS | 40.3 (11.2) | 40.5 (10.5) |
| PCS | 40.0 (9.3) | 40.5 (9.2) |
Extra-articular manifestations included uveitis, psoriasis and inflammatory bowel disease.
axSpA, axial spondyloarthritis; BASFI, Bath Ankylosing Spondylitis Functional Index; DESIR, Devenir des Spondyloarthropathies Indifférenciées Récentes; MCS mental component score, PCS physical component score; PGA, patient global assessment; PhGA. physician global assessment; SF-36, Short-Form 36 Health Survey.